Publications by authors named "Murielle Sabatiello"
Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients.
Expert Rev Clin Immunol
September 2021
Article Synopsis
- Psoriasis affects about 2% of children in Europe, with most cases manageable through topical corticosteroid treatments, while more severe cases may need phototherapy or systemic drugs that can have serious side effects.
- Over the past 15 years, several biologic treatments have been developed for moderate-to-severe plaque psoriasis, starting with etanercept and later including adalimumab, ustekinumab, secukinumab, and ixekizumab, which show better efficacy and safety compared to traditional therapies.
- Experts recommend ustekinumab, secukinumab, and ixekizumab as first-line treatments for moderate-to-severe psoriasis in children and adolescents due to their excellent outcomes and lower risk of adverse effects.